Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer

◇ RESEARCH

A narrative review summarizes evidence that the gut microbiome-immune axis regulates antitumor immunity and may mediate both primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR CRC. (Front Cell Infect Microbiol)